Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 13,522,000 | 13,367,000 | 13,294,000 | 12,694,000 | 16,783,000 |
| Cost of Goods | 3,976,000 | 3,938,000 | 3,914,000 | 4,039,000 | 4,217,000 |
| Gross Profit | 9,546,000 | 9,429,000 | 9,380,000 | 8,655,000 | 8,813,000 |
| Operating Expenses | 6,984,000 | 6,196,000 | 5,901,000 | 6,240,000 | 6,169,000 |
| Operating Income | 2,562,000 | 3,233,000 | 3,479,000 | 2,415,000 | 2,644,000 |
| Interest Expense | 206,000 | 202,000 | 201,000 | 202,000 | 201,000 |
| Other Income | 14,595,000 | 199,000 | 228,000 | 237,000 | 116,000 |
| Pre-tax Income | 16,951,000 | 3,230,000 | 3,506,000 | 2,450,000 | 2,559,000 |
| Income Tax | 645,000 | 472,000 | 611,000 | 391,000 | 460,000 |
| Net Income Continuous | 16,306,000 | 2,758,000 | 2,895,000 | 2,059,000 | 2,099,000 |
| Minority Interests | -2,000 | 0 | -1,000 | 0 | 5,000 |
| Net Income | $16,308,000 | $2,758,000 | $2,896,000 | $2,059,000 | $2,094,000 |
| EPS Basic Total Ops | 7.28 | 1.23 | 1.29 | 0.91 | 0.92 |
| EPS Basic Continuous Ops | 7.27 | 1.23 | 1.29 | 0.91 | 0.93 |
| EPS Diluted Total Ops | 7.22 | 1.22 | 1.28 | 0.91 | 0.92 |
| EPS Diluted Continuous Ops | 7.21 | 1.22 | 1.28 | 0.91 | 0.92 |
| EBITDA(a) | $2,562,000 | $3,233,000 | $3,479,000 | $2,415,000 | $7,945,000 |